Psychedelic Drug Market to Grow with a CAGR of 10.55% through 2030

Rising Prevalence of Mental Health Disorders and Growing Investments and Strategic Partnerships are expected to drive the Global Psychedelic Drug Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Psychedelic Drug Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Psychedelic Drug Market stood at USD 4.55 Billion in 2024 and is anticipated to grow with a CAGR of 10.55% in the forecast period.

Recent advancements in neuroscience and psychiatry have reignited interest in psychedelic compounds such as psilocybin, ketamine, LSD, and MDMA. Clinical trials conducted by leading research institutions, including Johns Hopkins University and Imperial College London, have produced compelling evidence demonstrating the efficacy of these substances in treating mental health disorders. Encouraging trial results have not only accelerated the regulatory approval process but have also bolstered investor confidence, driving increased pharmaceutical research and development in this sector.

Regulatory bodies across North America and Europe are increasingly acknowledging the therapeutic potential of psychedelics, leading to policy reforms that facilitate research and commercialization. The U.S. Food and Drug Administration (FDA) has granted "Breakthrough Therapy" designation to multiple psychedelic-based treatments, streamlining their clinical development. For instance, the Multidisciplinary Association for Psychedelic Studies (MAPS) is advancing MDMA-assisted therapy for PTSD, while COMPASS Pathways is progressing with psilocybin-based treatments for depression. These regulatory advancements are expediting market adoption and lowering entry barriers for new industry participants.

Once stigmatized, psychedelics are now gaining widespread recognition as legitimate medical treatments, thanks to educational initiatives and positive clinical trial outcomes. Medical professionals, mental health specialists, and policymakers are increasingly acknowledging their therapeutic benefits, leading to greater integration within mainstream healthcare systems. Countries such as Canada and Australia have pioneered progressive regulatory measures, allowing controlled medical access to certain psychedelic compounds, setting a precedent for broader global adoption.

Beyond drug development, the market is shifting toward structured treatment models that incorporate psychedelic-assisted therapy. Companies are establishing specialized clinics, therapy centers, and digital health platforms to offer medically supervised treatment programs, creating new business opportunities and driving revenue growth, particularly in North America and Europe.

The demand for alternative treatments in addiction recovery is also contributing to the expansion of the psychedelic drug market. Psychedelic-assisted therapy has demonstrated promising results in treating opioid and alcohol use disorders, with clinical studies showing that compounds like ibogaine and psilocybin can significantly reduce substance dependence and relapse rates. As the global opioid crisis continues to escalate, the need for innovative, evidence-based addiction treatments is expected to further drive market growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Psychedelic Drug Market”

The Global Psychedelic Drug Market is segmented into drug type, application, distribution channel, regional distribution, and company.

Based on its application, Treatment-Resistant Depression segment dominate the Global Psychedelic Drugs Market during the forecast period. Psychedelic compounds such as psilocybin, ketamine, and MDMA have been extensively studied for their effectiveness in treating TRD. Research conducted by institutions like Johns Hopkins University, Imperial College London, and Yale University has provided robust clinical evidence indicating that psychedelics can produce profound therapeutic benefits with just one or two sessions, compared to daily dosing with traditional medications. For instance, COMPASS Pathways' Phase IIb clinical trial on psilocybin for TRD demonstrated a statistically significant reduction in depression symptoms, positioning it as a breakthrough therapy in the field. Regulatory agencies are recognizing the potential of psychedelics in addressing TRD, leading to expedited approval pathways. The U.S. Food and Drug Administration (FDA) has granted "Breakthrough Therapy" designation to psilocybin and esketamine (a derivative of ketamine), accelerating their clinical development and regulatory review. Esketamine, marketed as Spravato by Janssen Pharmaceuticals, has already received FDA approval for TRD, setting a precedent for other psychedelic treatments to enter the market.

Based on region, The Asia Pacific region is emerging as the fastest-growing market in the global psychedelic drug industry, driven by shifting regulatory landscapes, rising mental health awareness, increasing investment in psychedelic research, and the expansion of healthcare infrastructure. While North America and Europe have traditionally dominated this sector, Asia Pacific is now witnessing a rapid transformation, creating significant growth opportunities for industry players. While psychedelic drug regulations in Asia Pacific have historically been stringent, governments and regulatory bodies are beginning to reassess their stance in light of growing scientific evidence supporting the therapeutic potential of psychedelics. Countries such as Australia have already taken a progressive approach, legalizing the use of MDMA and psilocybin-assisted therapy for certain mental health conditions under controlled medical supervision. This sets a precedent for other nations in the region to explore regulatory reforms that facilitate psychedelic research and medical applications. Several Asian governments are now supporting clinical trials to evaluate the safety and efficacy of psychedelics. For instance, Singapore’s Institute of Mental Health (IMH) has initiated research on psychedelics for depression and PTSD, while Japan and South Korea are exploring ketamine-based treatments for mental health disorders. These regulatory shifts are expected to accelerate approvals and market entry for psychedelic-based therapeutics in the coming years.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global psychedelic drug market is at a pivotal moment, with emerging trends pointing to a future that holds great promise. As regulatory acceptance expands, psychedelic therapies are poised to become integral to mental healthcare. Additionally, the integration of technology, the exploration of new indications, and the growth of psychedelic wellness programs are broadening the scope of their applications. Investment and advocacy efforts are further propelling this transformative industry. However, it is essential to balance innovation with safety and ethics to ensure that the potential benefits of psychedelic drugs are realized responsibly and with the best interests of patients in mind,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others), By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Psychedelic Drug Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Psychedelic Drug Market.